Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Cannabidiol (CBD) Products

Use Patterns and Perceptions Within a Sample of Anxious Users

Bibliographic Data

ID21645685
AuthorsL Riley Gournay (0000-0002-5192-8197, Department of Psychological Sciences, University of Arkansas, Fayetteville, AR, USA, corresponding author), Morgan L Ferretti (0000-0002-9580-2318, Department of Psychological Sciences, University of Arkansas, Fayetteville, AR, USA), Ivori Zvorsky (0009-0007-9101-2371, Canopy Growth Corporation, Charlotte’s Web, Louisville, CO, USA), Daniella A Fernandez (Department of Psychological Sciences, University of Arkansas, Fayetteville, AR, USA), Ellen W Leen-Feldner (Department of Psychological Sciences, University of Arkansas, Fayetteville, AR, USA), Ellen W Leen‐Feldner (0000-0002-8524-7090, University of Arkansas at Fayetteville)
Year2024
Volume59
Issue11
Pages1604-1612
Publication date2024-09-18
Open AccessNo
TypeARTICLE
VenueSubstance Use & Misuse (JOURNAL)
Journal identifiersISSN: 1082-6084 • E-ISSN: 1532-2491
PublisherInforma UK Limited (PUBLISHER • GB)
DOI10.1080/10826084.2024.2369153
PMID38946130
OpenAlexW4400218254
LanguageEN
References cited47

INTRODUCTION: Cannabidiol (CBD) shows promise for a variety of indications, including anxiety. Prior survey work indicates anxiety ranks as a top reason for which people use cannabidiol (CBD), but no work has evaluated individuals using CBD specifically for anxiety. METHOD: = 12.99) who reported using CBD products for anxiety-related concerns within the past 30 days. RESULTS: Family and friends, followed by popular and scientific literature, were the most common sources informing participants' decision to use CBD products to target anxiety. On average, participants reported using CBD products daily for at least a year and indicated it was very effective in targeting anxiety-related symptoms. The top three ranked symptoms improved by CBD products were subjective anxiety, difficulty falling asleep, and irritability. These findings were despite the fact that the most frequent dosing levels (∼50mg) were well below those empirically observed to yield anxiolytic effects. Most participants denied side effects, adding to the literature supporting CBD products' safety and tolerability. Finally, participants were generally poorly informed about the nature of CBD products (e.g., distinction from THC), suggesting a need for consumer education. CONCLUSION: Collectively, the current study extends prior survey work suggesting powerful expectancies about CBD products, particularly in terms of anxiety reduction, including among those using it to target anxiety-related symptoms. Findings also highlight the importance of addressing the gap between scientific and consumer knowledge

Cannabidiol · Cannabis · Chromatography · Perception · Psychiatry · Cannabis and Cannabinoid Research · Chemistry · Clinical Psychology · Medicine · Psychedelics and Drug Studies · Psychology · Substance Abuse Treatment and Outcomes

  • Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample.

    Martin M Antony, Peter J Bieling et al.•Psychological Assessment•1998

  • CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults

    Meghann Wheeler, Julie Williams Merten et al.•Substance Use & Misuse•2020

  • A Team-based Approach to Open Coding

    Open Access•M A Cascio, Eunlye Lee et al.•CAM•2019

Highly citedNo

Tools

Open DOI
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae